Inventor
Susanne KAMMLER
Inventor
DK
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations24%
C12NMicroorganisms or enzymes24%
A61KPreparations for medical, dental or toiletry purposes19%
C12YEnzymes14%
C07HSugars10%
Y02ATechnologies for adaptation to climate change10%
PatentTitleYear
12,497,621Oligonucleotides for modulating RTEL1 expression202512,303,525Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection202511,898,145Enhanced oligonucleotides for inhibiting RTEL1 expression202411,484,546Nucleic acid molecule for reduction of PAPD5 and PAPD7 mRNA for treating hepatitis B infection202211,155,816Oligonucleotide conjugates2021Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2021Patents assigned to ROCHE INNOVATION CT COPENHAGEN AS (1)· patent assignee history
2021–2025Based in DK· patent location history
2022–2025Patents assigned to HOFFMANN LA ROCHE (4)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| HOFFMANN LA ROCHE | 4 | 2022–2025 |
| ROCHE INNOVATION CT COPENHAGEN AS | 1 | 2021 |
Locations
| Location | Patents | Span |
|---|---|---|
| DK | 5 | 2021–2025 |